focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,796.00
Bid: 1,795.50
Ask: 1,796.00
Change: -16.50 (-0.91%)
Spread: 0.50 (0.028%)
Open: 1,792.50
High: 1,802.00
Low: 1,792.00
Prev. Close: 1,812.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

MARKET PULSE-AMD, Cbeyond, Halliburton, Plug Power, Prosensa, Sarepta

Mon, 21st Apr 2014 14:00

(For more market insights, including options activity, click on ; for the Day Ahead newsletter http://link.reuters.com/mex49s; for the Morning News Call newsletter, http://link.reuters.com/nex49s)

April 21 (Reuters) - U.S. stocks opened flat on Monday as investors found few reasonsto keep buying following a strong rally last week and ahead of aheavy week of corporate earnings. The Dow Jones industrialaverage was up 0.25 percent at 16,448.9, the S&P 500 was up 0.22 percent at 1,868.98 and the Nasdaq Composite was up 0.26 percent at 4,106.1.

** HALLIBURTON CO, $63.289, +3.92 pct

The world's No. 2 oilfield services company, reportedbetter-than-expected quarterly results, helped by robustdrilling activity in Russia, Saudi Arabia and Angola.

** HASBRO INC, $55.255, +1.18 pct

The toymaker reported a quarterly profit, compared with ayear-ago loss, helped by strong demand for its toys for girls.Sales of girls' toys such as My Little Pony and Nerf Rebelleincreased 21 percent to $138.7 million in the first quarterended March 30.

** SAREPTA THERAPEUTICS INC, $36.8001, +50.82 pct

** PROSENSA HOLDING NV, $5.55, +9.47 pct

Sarepta said it would start new trials to revive the chanceof approval for its experimental muscle disorder drug after theU.S. Food and Drug Administration advised the company to submitnew safety and efficacy data.

Prosensa makes drisapersen, a competing drug that failed alate-stage trial in September 2012.

** TEVA PHARMACEUTICAL INDUSTRIES LTD, $51.01,+0.31 pct

** MYLAN INC, $47.94, +2.17 pct

** MOMENTA PHARMACEUTICALS INC, $11.9984, +8.09 pct

The U.S. Supreme Court on Friday denied a request by Teva tostay a lower-court ruling in a patent case that favored thedevelopers of generic versions of the Israel-based company'stop-selling multiple sclerosis drug Copaxone.

The decision could help pave the way for generic competitorsof Teva's Copaxone drug to go on the market as soon as nextmonth.

The lower-court ruling in July 2013 was in favor of twoteams developing cheaper generic forms of Copaxone: onecomprising Novartis AG's Sandoz Inc and MomentaPharmaceuticals, and the other comprising Mylan Inc andNatco Pharma Ltd.

** CBEYOND INC, $9.79, +38.28 pct

Privately held enterprise Internet-based communicationsservices provider Birch Communications Inc said it agreed to buythe data center and networking services provider Cbeyond Inc forabout $323 million in cash to expand its optical fiber and datacenter network.

Cbeyond shareholders will get between $9.97 and $10 pershare. At $9.97 per share, the offer represents a premium of40.8 percent over the closing price of Cbeyond's stock onThursday.

** PLUG POWER, $8.03, +9.70 pct

The US fuel cell maker said on Monday Chief Executive AndyMarsh will provide update on the company's plans for its GenKeyhydrogen fuel cells, and ReliOn acquisition At 10 am ET.

** ADVANCED MICRO DEVICES INC, $4.14, +12.20 pct

The chipmaker reported better-than-expected quarterlyresults on Thursday and its second-quarter revenue forecast wasabove analysts' estimates.

At least two brokerages raised their price targets on thestock on Monday.

** CALPINE CORP, $22.28, +4.26 pct

U.S. power and energy infrastructure owner LS Power EquityAdvisors LLC said it has agreed to buy about 3,500 MW ofgeneration resources in the southeastern United States fromCalpine for $1.57 billion. The portfolio consists of sixcombined-cycle generation facilities which use natural gas asthe primary fuel source, LS Power Equity said.

Calpine mainly owns and operates natural gas-fired andgeothermal power plants in North America.

** PERFECT WORLD CO LTD, $19.335, -1.20 pct

** SHANDA GAMES LTD, $6.71, +1.36 pct

China-based online game developer Perfect World said itjoined the consortium offering to buy rival Shanda Games.Perfect World said it would buy 30.3 million class A ShandaGames shares for $100 million from Shanda InteractiveEntertainment Ltd, a shareholder in Shanda Games.

** NU SKIN ENTERPRISES INC, $87.52, +1.27 pct

The direct-selling skincare and nutritional product companyon Saturday said its Nu Skin China unit plans to immediatelyresume corporate-hosted business meetings and will beginaccepting applications for new sales people on May 1.

"China is an important marketplace for Nu Skin and we arecommitted to operating in full compliance with China's directselling regulations to promote long-term success," the companysaid in a statement.

** TREEHOUSE FOODS INC, $72.38, +0.32 pct

The food manufacturer said it will acquire Canada-basedProtenergy Natural Foods from Whitecastle Investments Ltd,Whitecap Venture Partners and others for about C$170 million.

Protenergy Natural Foods makes private-label broth, soupsand gravies.

** GENERAL MOTORS CO, $33.95, -0.09 pct

The U.S. car giant plans to invest $12 billion in China from2014 to 2017 and build more plants next year as it competes withaggressive rivals in the world's largest auto market.

** NEWMONT MINING CORP, $25.01, +6.24 pct

The talks between Barrick Gold Corp and NewmontMining over a combination that would create a gold miningbehemoth have hit a snag, but two sources close to the situationsay the companies remain keen on a deal and discussions arelikely to resume.

** PFIZER INC, $30.71, +1.52 pct

The U.S. pharmaceutical giant has approached British rivalAstraZeneca Plc to propose a 60 billion pound ($101billion) takeover, Britain's Sunday Times reported.

** APPLE INC, $527.78, +0.54 pct

** GOOGLE INC, $539.44, -0.72 pct

Apple and Google are wooing game developers to ensure thattop game titles arrive first on devices powered by theirrespective operating system, the Wall Street Journal reported,citing people familiar with the matter.

** COMCAST CORP, $49.61, +1.04 pct

** CHARTER COMMUNICATIONS INC, $121.75, +3.33 pct

Comcast is in talks with Charter Communications over sellingor spinning off roughly 3 million subscribers worthapproximately $18 billion to $20 billion as part of thedivestitures related to its $45.3 billion takeover of TimeWarner Cable, according to a source familiar with thematter.

** VIMPELCOM LTD, $9.325, +3.61 pct

Russia's Vimpelcom has resolved a long-running dispute withthe Algerian government by selling it a majority stake in thecountry's biggest telecoms operator for $2.6 billion, while itwill keep control and slash debt.

** WALT DISNEY CO, $79.49, -0.63 pct

Walt Disney Co's cable networks are expected to record highsingle-digit growth in operating income and domestic affiliaterevenue from fiscal 2014 through 2016, Chief Financial OfficerJay Rasulo told investors on Thursday.

** SPRINT CORP, $8.57, +0.59 pct

** T-MOBILE US INC, $30.44, +0.13 pct

A possible merger between Sprint and T-Mobile could promptU.S. regulators to rewrite rules they are now weighing for a2015 auction of airwaves, according to sources familiar with theproposed regulations.

** LULULEMON ATHLETICA INC, $49.854, -3.59 pct

A U.S. judge has issued final dismissals of lawsuitsaccusing Lululemon and various company officials of defraudingshareholders by concealing defects in yoga pants.

** ATHENAHEALTH, $138.736, -4.70 pct

The healthcare IT services company on Thursday reportedfirst-quarter adjusted earnings and revenue that fell below WallStreet estimates.

Three brokerages, including Oppenheimer, Deutsche Bank andB. Riley cut their price targets on the company' stock, citingweakness in its Epocrates business - a mobile medicalapplication.

** SELECT COMFORT CORP, $18.98, +6.93 pct

The specialty mattress maker on Thursday reportedfirst-quarter sales that beat analysts' estimates, helped by a 2percent rise in comparable sales.

** WEIBO CORP, $22.65, +11.91 pct

The Chinese Twitter-like messaging service company'sU.S.-listed shares were up premarket on Monday after they soared19 percent on their debut on Thursday.

** UNITEDHEALTH GROUP INC, $76.3, +0.69 pct

The largest U.S. health insurer, said it spent more than$100 million to cover a pricey new hepatitis C drug from GileadSciences Inc in its first three months on the market,an amount that was "multiple" times what it had expected.

** ABBOTT LABORATORIES, $38.81, -0.31 pct

An Abbott Laboratories spinoff urged a federal appealscourt to revisit a ruling in a case against GlaxoSmithKline Plc, but without disturbing landmark constitutionalprotections for gays and lesbians.

** KRAFT FOODS GROUP INC, $56.83, -0.14 pct

Kraft Foods is recalling about 96,000 pounds of Oscar MayerClassic Wieners because the packages may instead contain ClassicCheese Dogs made with milk, a known allergen.

** PLATINUM UNDERWRITERS HOLDINGS LTD, $62.35, +0.31pct

Brokerage Keefe Bruyette & Woods raised the reinsuranceprovider's target price to $69 from $67, after the company'searnings for the quarter ended March 31 beat analysts' estimateswith strong underwriting, investing, and capital managementperformance. The company reported earnings per share of $2.27,higher than analysts' average estimate of $1.28, according toThomson Reuters I/B/E/S. [ID: nPn5HRfMd]

** AMERICAN TOWER CORP, $82.44, -0.25 pct

Indian conglomerate Reliance Industries Ltd' telecommunications unit, which holds nationwide 4G permits, hasagreed to lease mobile phone masts from infrastructure providerAmerican Tower Corp's local arm, the companies said in astatement on Monday.

** CHINDEX INTERNATIONAL INC, $23.69, +3.27 pct

Chinese drugmaker Shanghai Fosun Pharmaceutical Group Co Ltd has raised its offer for U.S.-listed ChindexInternational Inc by 15 percent to $223.6 million aftera bidding war for the China-focused hospital chain.

** PEOPLE'S UNITED FINANCIAL INC, $14.65, +0.76 pct

Brokerage Keefe Bruyette & Woods cut the lender's targetprice to $14.50 from $15, citing low profitability until thecompany improves return on assets and efficiency ratio.

** PRIVATEBANCORP INC, $29.93, +1.15 pct

KBW raised its price target on the stock to $34 from $33after the bank reported better-than-expected first quarterresults on Thursday, helped by commercial loan growth.

** LINEAR TECHNOLOGY CORP, $46.33, -0.09 pct

The analog chipmaker said on Thursday it expects revenue togrow 2-6 percent from $348 million in the third quarter, that is$355-$369 million. Analysts on average were expecting revenue of$365 million, according to Thomson Reuters I/B/E/S.

** RADIOSHACK CORP, $1.47, +4.26 pct

The struggling U.S. electronics chain is mired in talks withits lenders over its plans to close about 1,100 stores,complicating its turnaround efforts, the Wall Street Journalreported, citing sources close to the talks.

RadioShack, which operates about 4,300 stores in the UnitedStates, said in March that the plan needed permission from itslenders, adding that its credit agreements allowed it to closeonly about 200 stores without the approval of lead lenders, theJournal said late on Wednesday. (http://r.reuters.com/vyg68v)

The company reported a wider quarterly loss and a huge dropin sales during the holiday season.

** BIOGEN IDEC INC, $294.058, +1.21 pct

Biogen is pricing its newly approved long-acting hemophiliadrug, Alprolix, to cost U.S. patients, and insurers, about thesame per year as older, less convenient therapies whose pricecan reach about $300,000 annually.

The move could pressure rivals such as Pfizer Inc tolower prices for existing hemophilia treatments, which providepatients with life-saving infusions of a blood clotting agent,according to doctors and industry analysts.

** HILLSHIRE BRANDS CO, $36.14, +0.08 pct

The maker of Jimmy Dean sausages and Ball Park hot dogs saidit has signed a definitive agreement to acquire Van's NaturalFoods from private equity firm Catterton Partners for about $165million to expand its presence in the frozen foods category.

Van's Natural Foods makes frozen waffles and breakfastsandwiches, as well as gluten-free cereals and crackers. (Compiled by Rohit T.K. in Bangalore; Editing by Joyjeet Das)

More News
1 Nov 2023 08:51

TOP NEWS: GSK ups guidance as boosted by Shingrix and Arexvy

(Alliance News) - GSK PLC on Wednesday hailed the performance of the world's first approved respiratory syncytial virus vaccine Arexvy, as it reported a rise in profit and revenue.

Read more
1 Nov 2023 08:50

LONDON MARKET OPEN: FTSE 100 up, FTSE 250 down as Aston Martin tumbles

(Alliance News) - Stock prices in London opened mixed on Wednesday, ahead of key central bank decisions, as investors were cheered by some strong updates from large-cap listings.

Read more
1 Nov 2023 07:40

LONDON BRIEFING: GSK raises annual guidance following Arexvy launch

(Alliance News) - Stocks in London are called higher on Wednesday, with the main focal point for the day being the upcoming US interest rate decision.

Read more
1 Nov 2023 07:27

GSK hikes guidance after strong third quarter

(Sharecast News) - GSK announced a robust third quarter on Wednesday, prompting an upgrade to its full-year guidance.

Read more
30 Oct 2023 09:01

IN BRIEF: GSK says Jemperli meets endpoint in endometrial cancer trial

GSK PLC - Brentford, west London-based pharmaceutical maker - Jemperli, whose generic name is dostarlimab, meets endpoint of overall survival in phase III Ruby trial on adult patients with primary advanced or recurrent endometrial cancer. Jemperli, combined with standard-of-care chemotherapy, followed by dostarlimab, demonstrated a "statistically significant and clinically meaningful benefit" to the patients in the trial.

Read more
30 Oct 2023 07:06

GSK's Jemperli sees success in endometrial cancer trial

(Sharecast News) - GSK reported encouraging outcomes from part one of the 'RUBY' phase three trial evaluating the efficacy of 'Jemperli', or dostarlimab, with standard chemotherapy for treating adult patients with advanced or recurrent endometrial cancer on Monday.

Read more
26 Oct 2023 09:19

TOP NEWS: GSK subsidiary ViiV receives HIV drug approval in China

(Alliance News) - GSK PLC on Thursday said its subsidiary ViiV Healthcare has received marketing authorisation in China for its cabotegravir treatment, marketed as Vocabria.

Read more
26 Oct 2023 07:02

GSK HIV injection regimen gets approval in China

(Sharecast News) - GSK announced on Thursday that its majority-owned HIV specialist subsidiary ViiV has received approval from the National Medical Products Administration (NMPA) of China for an injection regimen.

Read more
25 Oct 2023 16:01

UK earnings, trading statements calendar - next 7 days

Thursday 26 October 
Bank of Ireland Group PLCTrading Statement
Bloomsbury Publishing PLCHalf Year Results
Botswana Diamonds PLCTrading Statement
C&C Group PLCHalf Year Results
e-Therapeutics PLCHalf Year Results
Financials Acquisition CorpTrading Statement
GCP Infrastructure Investments LtdTrading Statement
HarbourVest Global Private Equity LtdHalf Year Results
Hummingbird Resources PLCTrading Statement
Hunting PLCTrading Statement
Inchcape PLCTrading Statement
International Personal Finance PLCTrading Statement
PPHE Hotel Group LtdTrading Statement
Renishaw PLCTrading Statement
Standard Chartered PLCQ3 Results
Unilever PLCTrading Statement
WPP PLCTrading Statement
Friday 27 October 
International Consolidated Airlines Group SAQ3 Results
NatWest Group PLCQ3 Results
Monday 30 October 
Airtel Africa PLCHalf Year Results
Computacenter PLCTrading Statement
Glencore PLCTrading Statement
HSBC Holdings PLCQ3 Results
Lok'n Store Group PLCFull Year Results
Pearson PLCTrading Statement
Tuesday 31 October 
BP PLCQ3 Results
Coca-Cola HBC AGTrading Statement
Elementis PLCTrading Statement
essensys PLCFull Year Results
Georgia Capital PLCQ3 Results
Grit Real Estate Income Group LtdFull Year Results
RHI Magnesita NVTrading Statement
Spectris PLCQ3 Results
TP ICAP Group PLCTrading Statement
UP Global Sourcing Holdings PLCFull Year Results
Wednesday 1 November 
Asos PLCFull Year Results
Aston Martin Lagonda Global Holdings PLCQ3 Results
Beximco Pharmaceuticals LtdFull Year Results
GSK PLCQ3 Results
Next PLCTrading Statement
Smurfit Kappa Group PLCTrading Statement
Weir Group PLCTrading Statement
  
Copyright 2023 Alliance News Ltd. All Rights Reserved.

Read more
25 Oct 2023 09:35

GSK says RSV jab shows promising response in adults aged 50 to 59

(Alliance News) - GSK PLC on Wednesday said a trial found its respiratory syncytial virus vaccine Arexy delivered an immune response in adults aged 50 to 59.

Read more
25 Oct 2023 07:27

GSK hails success in US RSV vaccine trial

(Sharecast News) - Pharma giant GSK has announced positive preliminary results from a trial of its Arexvy vaccine to treatment respiratory syncytial virus (RSV) disease for a younger patient population in the US.

Read more
16 Oct 2023 08:09

TOP NEWS: GSK receives positive EU opinion on Jemperli for cancer

(Alliance News) - GSK PLC on Monday said its monoclonal antibody Jemperli is closer to becoming the first new frontline treatment option in the EU in decades for a certain form of endometrial cancer.

Read more
16 Oct 2023 07:44

LONDON BRIEFING: Hipgnosis pulls interim dividend on lower royalties

(Alliance News) - The FTSE 100 is likely to open higher on Monday, benefitting from higher oil and gas prices, while fears of escalating regional conflict in the Middle East damp risk sentiment elsewhere.

Read more
16 Oct 2023 07:16

GSK nears green light for Jemperli usage in Europe

(Sharecast News) - Pharma giant GSK has announced that European experts recommended the approval of its Jerperli drug for the treatment of a specific type of endometrial cancer - paving the way for marketing authorisation by the continent's regulatory body.

Read more
11 Oct 2023 11:51

GSK settles California Zantac lawsuit

(Sharecast News) - GSK has agreed to settle another lawsuit concerning its discontinued heartburn treatment Zantac, the drugs giant confirmed on Wednesday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.